Abstract: In one aspect, the present disclosure provides a complex containing kojyl methylenedioxycinnamate; a compound containing an ethylene glycol moiety or a propylene glycol moiety; a surfactant containing a saccharide moiety; and an antioxidant, and an emulsion formulation containing the complex. In another aspect, the present disclosure provides a method for manufacturing the complex, comprising: (a) adding kojyl methylenedioxycinnamate, a compound containing an ethylene glycol moiety or a propylene glycol moiety, a surfactant containing a saccharide moiety, and an antioxidant; and (b) homomixing the result of the (a).

Abstract: A cis-platinum(II)-oligomer hybrid capable of targeting purine-rich targets in genomic DNA, and crosslinking the DNA, is described. The hybrids are generated by conjugating an azide-modified cis-platinum(II) complex with an alkyne-modified monomer of an oligomer by azide-alkyne cycloaddition, in which the oligomer comprises at least 10 contiguous nucleobase-bearing monomers. The oligomer may be a triplex-forming oligonucleotide. Methods of treating proliferative disorder such as cancer are also described.

Abstract: The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.

Abstract: A polypeptide-coupled small molecule compound and its antiviral applications are provided. The polypeptide-coupled small molecule compound is obtained by linking a polypeptide with a sequence X?nLXGG and a small molecule compound capable of inhibiting activity of papain-like protease (PLpro) of coronavirus through a chemical bond. The polypeptide with the sequence X?nLXGG is a polypeptide with a sequence LXGG at its carboxyl terminal, X and X? are independently any amino acid, and n is an integer between 1-50. The structure of the small molecule compound capable of inhibiting the activity of PLpro contains an amino group or a hydroxyl group. The polypeptide-coupled small molecule compound can inhibit the PLpro of SARS-CoV-2 in a targeted manner, thereby inhibiting the polyprotein cleavage of coronavirus in the host, and achieving the purpose of inhibiting the replication of coronavirus in the host. It has the advantages of synergistic inhibition, low cytotoxicity and favorable solubility.

Abstract: Provided herein are oligomeric compounds comprising a bicycle ligand and a modified oligonucleotide. This compound may comprise a bicycle ligand as the cell-targeting moiety, and may also comprise a conjugate linker to connect the bicycle ligand and modified oligonucleotide. This compound may be used in conjunction with a pharmaceutically acceptable salt.

Abstract: The present disclosure relates to nanoparticle compositions for modifying antigen-specific T cells and uses thereof.

Abstract: A drug conjugate of an Eribulin derivative. Specifically, provided are an HER2 antibody conjugate that is formed by binding the Eribulin derivative to structural domain II of HER2, a preparation method therefor, and a pharmaceutical application thereof. The present invention further relates to a method for treating a cancer by means of administration of an antibody-drug conjugate, and a composition.

Abstract: The present disclosure relates to conjugates of novel camptothecin analogs with a cell binding molecule of formula (I). It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of application the conjugates in targeted treating of cancer.

Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Abstract: The present disclosure provides nectin-4 antibodies and oligonucleotide conjugates thereof. Also provided are related methods of preparation thereof and methods of use thereof, including therapeutic uses.

Abstract: The present disclosure relates generally to antibody-drug conjugates comprising peptide-containing linkers and to methods of using these conjugates as therapeutics and/or diagnostics. Also disclosed herein are peptide-containing scaffolds useful to conjugate with a targeting moiety (e.g., an antibody), a drug, or both to produce the antibody-drug conjugates.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: An exemplary embodiment of the present disclosure provides compositions and methods of using compositions. A composition described herein comprises a hydrogel, a therapeutic species, and a linker joining the hydrogel to the therapeutic species. The linker joining the hydrogel to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Some aspects of this disclosure relate to methods of delivering a therapeutic species to a subject. The method comprises disposing the composition in the subject and initiating a retro Diels-Alder reaction to decompose the Diels-Alder cyclo-addition product, thereby severing the linker and decoupling the therapeutic species from the hydrogel.

Abstract: The present disclosure relates to a composition comprising a first amphiphile and optionally a second amphiphile each having the formula S-[B]-[U]-H-[D] and at least one drug molecule is noncovalently associated with or covalently bonded directly or via a suitable linker X1 to the first amphiphile and/or to the optional second amphiphile. The composition is useful in treating a cancer, an infectious disease or an inflammatory disease.

Abstract: A composition for enhancing radiation therapy includes a complex including micelles formed of amphiphilic molecules in which a hydrophilic portion and a hydrophobic portion are bound by a reactive oxygen species (ROS) cleavable linker, and manganese oxide particles supported on cores of the micelles and hydrophobically modified by binding a hydrophobic substituent to the surface thereof. By supporting hydrophobic manganese oxide particles in the micelles, the complex is stably protected in vivo and easily delivered to a tumor site. The micelles have a hydrophilic portion and a hydrophobic portion bound by a ROS cleavable linker to be degraded in response to a ROS of a target site, and thus can efficiently release the hydrophobic manganese oxide particles. The released hydrophobic manganese oxide particles generate oxygen and changes the microenvironment of the target site, and thus may enhance the therapeutic effect of a drug carried on the micelles.

Abstract: A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant. The nanocarrier comprises a porous silicate matrix and particles of a magnetic ferrite disposed in the pores of the porous silicate matrix. The pharmaceutical agent mixture is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.

Abstract: Disclosed herein include compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with tropisms to the central nervous system, the peripheral nervous system, and/or the lung, with increased specificity and transduction efficiency. Also described include methods of treating various diseases and conditions using the rAAVs.

Abstract: Disclosed is a composition for treating a neurological disease caused by nerve injury, including an isolated polynucleotide of a 5?-untranslated region (5?UTR) of a Gpr151 gene or a variant thereof. Also disclosed are a novel variant polynucleotide of 5?UTR of a Gpr151 gene and a vector including the polynucleotide.

Abstract: A plasmid platform according to an embodiment includes a nucleic acid sequence encoding a modified protein from which an intracellular domain, an extracellular domain, or a combination thereof of lysosome-associated membrane glycoprotein 2B (LAMP-2B) has been removed, and is based on the discovery that removing a specific domain of LAMP-2B significantly stabilizes the expression of intended biomolecules and significantly increases the efficiency with which intended biomolecules are delivered. The plasmid platform is expected to provide high technical utility in the expression and delivery of proteins of interest, particularly expression and delivery using exosomes, and may be expanded to various associated technical fields or uses.

Abstract: Provided herein are compositions and methods of using prime editing systems comprising prime editors and prime editing guide RNAs for treatment of genetic disorders.

Abstract: This invention relates to compositions, methods, strategies, and treatment modalities related to the epigenetic modification of hepatitis B virus (HBV) genes.

Abstract: This invention relates to compositions, methods, strategies, and treatment modalities related to the epigenetic modification of hepatitis B virus (HBV) genes.

Abstract: Provided are nucleic acid-based expression constructs for the targeted production of a therapeutic protein within a cell that is associated with aging, disease, another condition. Also provided are vectors and systems for the delivery of those nucleic acid-based expression constructs as well as methods for using such nucleic acid-based expression constructs, vectors, and systems for reducing, preventing, and/or eliminating the growth and/or survival of an age-, disease-, or condition-associated cell and for the treatment of a disease or condition that is associated with an age, disease, or condition associated cell.

Abstract: The present disclosure relates to Fibroblast Activating Protein (FAP) targeted compounds conjugated to near-infra red (NIR) dyes and methods for their therapeutic and diagnostic use. More specifically, this disclosure provides compounds and methods for diagnosing and treating diseases associated with cells and/or vasculature expressing Fibroblast Activating Protein (FAP). The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

Abstract: Some embodiments disclosed herein pertain to indicator compounds used to detect the presence of and/or an amount of an analyte. In some embodiments, the indicator compounds are fusion proteins. In some embodiments, when the analyte binds to the indicator compound, the indicator compound undergoes a conformational change. In some embodiments, the conformational change results in a luminescent signal that allows quantification of the amount of analyte present.

Abstract: The present invention provides lipid nanoparticles that are amenable to an irradiation at a wavelength at or above 850 nm, have an absorption peak from about 850 to 1100 nm wavelength, and comprise a high transition temperature lipid and a dye (e.g., a J-aggregate of a dye). In some embodiments, the dye (e.g., J-aggregate of the dye) is encapsulated in the lipid nanoparticle. In various embodiments, the present invention also relates to compositions comprising said lipid nanoparticles and methods of generating said lipid nanoparticles and compositions thereof. The present invention further relates to methods relating to the said lipid nanoparticles for imaging, detection, and treatment of diseases or disorders (e.g., phototherapy) in a subject.

Abstract: The present disclosure belongs to the field of functional fiber materials, and discloses a non-metallic temperature-responsive composite for magnetic resonance imaging (MRI), and a preparation method and use thereof. An organic hydrogen-containing molecular contrast agent is loaded into a polymer fiber through electrospinning, and the phase structure and molecular motility of the organic hydrogen-containing molecular contrast agent are controlled to regulate its relaxation time. The non-metallic temperature-responsive composite can achieve an “on/off” temperature-responsive MRI effect for a polymer material without the addition of an additional magnetic field. Compared with the prior art, an additional magnetic field is not required; the selected contrast agent is non-toxic or exhibits low toxicity to the human body; and an “on/off” imaging effect can be realized, where the advantages of nuclear magnetic resonance (NMR) signals of the material itself will not be affected when imaging is not conducted.

Abstract: Provided herein are polymeric particles and compositions (i.e., “backpacks”) that can adhere to cells and provide delivery of payload agents to those cells, and/or direct therapeutic activity of those cells.

Abstract: Imaging and radiotherapeutic agents targeting fibroblast-activation protein-? (FAP-?) and/or prostate-specific membrane antigen (PSMA) and their use in imaging and treating FAP-? and/or PSMA-related diseases and disorders are disclosed.

Abstract: The present application relates to a compound or a pharmaceutically acceptable salt and/or solvate thereof comprising one or more circulation enhancing groups, one or more target binding groups, one or more chelating groups, at one least cleavable linker and at least one branching group that is at least trivalent. The application further includes a radionuclide complex or a pharmaceutically acceptable salt and/or solvate thereof, comprising a compound of the application or a pharmaceutically acceptable salt and/or solvate thereof, and one or more radionuclides, and to compositions comprising the compound or the complexes. The present application also includes methods of using the compounds, complexes and compositions for targeting and/or killing target cells.

Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).

Abstract: The present invention relates to methods of preparation of a solution comprising an 18F labelled silyl-fluoride compound. Compounds and compositions obtained by the methods of the invention may be useful as positron emission tomography (PET) imaging agents. Compounds and compositions obtained by the methods of the invention may be useful in the diagnosis or imaging of angiogenesis or cancer.

Abstract: The present invention relates to compounds that can complex a radionuclide and formulations and kits comprising compounds that can complex a radionuclide. The compounds, formulations and kits are of use in radiotherapy and diagnostic imaging.

Abstract: Flexible diffuse-reflective smart camber (FDRSC) devices are disclosed herein. The devices include UV-C lights sources and an irradiance chamber. The irradiance chamber is open on at least one end through which the plants to be treated are exposed to the UV-C irradiance. Further, the inner surfaces of the irradiance chamber are covered by or consist of a diffuse reflective material that passively intensifies and uniformly distributes the UV-C irradiance to penetrate plant canopies. Also described herein are autonomous vehicles for moving the FDRSC devices across fields of crops and other plants. which is controlled in real time by a dosing control system. Also described herein are methods of in-situ UV-C treatment of plants using the FDRSC devices.

Abstract: The use of plasma to clean or sterilize surfaces can be particularly advantageous for surfaces that cannot be readily washed or cleaned by standard methods. The toxicity and complications generating sufficient plasma makes it hard to use for such purposes. The subject invention addresses the problem by generating a minimal amount of highly reactive plasma to sterilize a surface. This is achieved by reducing the amount of space and ambient air around and within the surface. In this way, the plasma generated fills only the required volume of the surface to be cleaned and the plasma is directed at the surface, not directed at or released into non-target areas.

Abstract: An adaptive footwear sanitization device is disclosed. The device may include a base plate having a first portion and a second portion. The device may further include a plurality of first light sources disposed in the first portion and a plurality of second light sources disposed in the second portion. The device may further include a detection unit configured to detect a footwear presence on a base plate top surface. The device may additionally include a controller that may identify one or more first light sources from the plurality of first light sources covered by the footwear based on inputs obtained by the detection unit. The controller may activate the one or more first light sources and the plurality of second light sources responsive to identifying the one or more first light sources. The first and second light sources may emit light to sanitize footwear bottom portion.

Abstract: A writing utensil sanitizing assembly and method for sanitizing a writing utensil prior to and after using the writing utensil to prevent the spread of germs and bacteria from touching the writing utensil includes a housing having a first end wall, a second end wall, and a perimeter wall attached to and extending between the first and second end walls. The first end wall has a first aperture extending therethrough, and the second end wall has a second aperture extending therethrough. The first and second apertures receive the writing utensil. An absorbent medium is positioned within the housing and has an open conduit extending therethrough and receives the writing utensil such that the writing utensil abuts a surface of the open conduit. The absorbent medium absorbs a sanitizing fluid for application onto the writing utensil when the writing utensil passes through the open conduit.

Abstract: An apparatus for ejecting one or more substances is disclosed. The apparatus includes a housing including an upper portion and a lower portion, wherein the lower portion of the housing includes flexible materials. The apparatus includes a cover configured to cover the upper portion of the housing. The apparatus includes one or more reservoirs configured to store one or more substances within the lower portion of the housing. The apparatus includes one or more protruding components configured to mix the one or more substances within the one or more reservoirs, wherein one or more protruding components are located inside the one or more reservoirs. The apparatus includes a flow port configured fluidically connect the one or more reservoirs to the ejector. The apparatus includes the ejector configured to eject the one or more substances from the flow port.

Abstract: The present invention is a composition and method of using the composition to neutralize or eliminate odors on a surface. In one aspect, the chemical formulation is an aqueous solution of multi-valent citrate salts and a surfactant that may further comprise a chelating agent. The method comprises the steps of applying this formulation in sufficient volume to saturate the surface thereby neutralizing or eliminating the odor. In another aspect, the formulation of multi-valent citrate salts may be applied in solid form to an odorous aqueous solution or may be used to coat an absorbent matrix that is expected to receive an odorous aqueous solution.

Abstract: Methods of manufacturing a porous device for diffusing a fragrance using additive manufacturing including iteratively spreading a loose powder and selecting at least one process parameter to create a porosity within the porous device adapted to carry the fragrance from a fragrance reservoir to an exterior surface of the porous device. An additively manufactured device for diffusing a fragrance includes a diffuser having a plurality of pores defining a porosity of the diffuser, the porosity defining at least one of a rate of absorption, an amount of storage, and a rate of diffusion of the fragrance. A method of using a porous device includes filling the plurality of pores with fragrance and diffusing the fragrance from an exterior surface.

Abstract: A wearable electronic device for providing or affecting smell. The wearable electronic device includes one or more odor manipulation units and a control circuit arrangement operably coupled with the one or more odor manipulation units for operating the one or more odor manipulation units. Each of the one or more odor manipulation units is respectively operable to provide or affect smell perceivable by a user of the wearable electronic device.

Abstract: A fragrance diffuser includes a housing configured to house at least two fragrance containers each containing a corresponding one of at least two fragrances. The fragrance diffuser also includes at least two dispensers each configured to dispense a corresponding one of the at least two fragrances from a corresponding one of the at least two fragrance containers when the at least two fragrance containers are housed by the housing. The fragrance diffuser further includes an electronic controller configured to operate the fragrance diffuser in at least one of a timed rotation mode, a shuffle mode, a blend mode, or a run-through mode.

Abstract: Methods of using an aroma device associated with food experiences are disclosed. A method can include obtaining food-product data corresponding to a food product; based on such data, selecting an aroma profile for the food product; emitting an aroma based on the profile; obtaining modification data; and generating a new aroma profile for the food product based on the modification data. A method can include decoupling two or more aromas based on human and pet aroma sensitivity and/or preferences. Systems configured to use an aroma device are also provided.

Abstract: A disinfecting and virus inactivating device performs disinfection treatment or inactivation treatment in a target space that a moving body enters and exits. The disinfecting and virus inactivating device includes a locus detection module configured to detect a movement locus of locations where the moving body comes into contact with respective objects or respective portions of an object in the target space, a substance generating module configured to generate a particular substance for use in the disinfection treatment or the inactivation treatment, and a transmission module configured to generate an air flow and transmit the particular substance generated by the substance generating module to the movement locus.

Abstract: A packaging system for the storage of an ophthalmic device is disclosed. The packaging system includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution containing (a) one or more osmoprotectants, (b) one or more poloxamer comfort agents and (c) one or more polyol demulcents, wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

Abstract: Disclosed embodiments relate to a wound dressing which can generate nitric oxide. The wound dressing may include a cover layer, a nitric oxide source layer, such as a nitrite providing layer, an absorbent layer such as a foam, and a gel material adhered to the absorbent layer. The gel material may include perforations in a cured pattern structure. The perforations may define a plurality of fluid channels extending through the gel material. The gel material may form an active wound contact layer for use in generating nitric oxide.

Abstract: The present invention is about a method of preparation and a pharmaceutical form of an injectable intramammary teat sealing composition for use in the veterinary industry. Intramammary teat sealant composition, which includes organic glyceryl monostearate or calcium stearate, with particle size between 30 and 100 ?m, in addition to mineral oil, titanium dioxide and stabilizer, in the absence of water.

Abstract: The present invention relates to a polyacrylamide hydrogel for use in prevention and/or treatment of osteoarthritis for at least 26 weeks in humans diagnosed with KL grade 2 and/or KL grade 3 osteoarthritis. Thus, a long term prevention and/or treatment of osteoarthritis patient sub-groups is achieved.

Abstract: Provided is a biocompatible composition or the like that assists cells in the repair of a damaged tissue in a joint cavity. The biocompatible composition or the like according to the disclosure includes a biocompatible polymer having a substituent that adheres or binds to cells and/or a soft tissue in a joint cavity.

Abstract: The composition comprises a polyol crosslinked with a) a multifunctional epoxide; or b) an epihalohydrin; or c) a molecule or crosslinker mixture comprising multiple epihalohydrin and/or epoxide groups or molecules. The composition has a number N1 of effective ether crosslinks per crosslinker molecule as calculated by subtracting 1 from the average number of distinct polyol repeat units bound per crosslinker molecule. The remaining reactive groups on the crosslinker are ineffective in crosslinking and provide a number N2 of pendant groups per crosslinker molecule. Among the N2 groups per crosslinker there are N3 groups per crosslinker that are unreacted or otherwise retain reactivity against nucleophiles. The relationship between N1 and N2 is: N1>0.35 (N1+N2).